Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The directors ("**the Directors**") of the board (the "**Board**") of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**") is pleased to announce that, based on the nomination of the nomination committee of the Board and the deliberation by the Board, the Board proposed to appoint Mr. Liu Hongkang (劉弘康先生) ("**Mr. Liu**") as a non-executive Director at the Board meeting held on January 27, 2026.

The biographical details of Mr. Liu are set out as follows:

Mr. Liu Hongkang (劉弘康先生), aged 35, joined SDIC Venture Capital Management Co., Ltd. (國投創業投資管理有限公司) since June 2021 and is currently serving as an investment manager in this company. Mr. Liu received his bachelor's degree in biotechnology and his doctorate degree in biophysics from Huazhong University of Science and Technology (華中科技大學) in the PRC in 2012 and 2020, respectively.

As at the date of this announcement, save as disclosed above, Mr. Liu has confirmed that (i) he has not held any position in the Company or any other members of the Company; (ii) he has not held any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) he has no relationship with any Directors, senior management, substantial or controlling shareholders of the Company; (iv) he does not hold any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) he has not received any punishment or regulatory sanction imposed by the China Securities Regulatory Commission and other relevant authorities or stock exchanges.

Mr. Liu will enter into a service contract with the Company and will not receive remuneration for his position as a non-executive Director.

As at the date of this announcement, save as disclosed in this announcement, the Board is not aware of any other information which shall be disclosed nor is/was Mr. Liu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**"), and there is no other matter in relation to his appointment that needs to be brought to the attention of the shareholders (the "**Shareholders**") of the Company and the Hong Kong Stock Exchange.

The proposed appointment of Mr. Liu as a non-executive Director is subject to the approval of the Shareholders by way of ordinary resolution at an extraordinary general meeting of the Company (the "**EGM**"). The term of office commences from the date of approval by the Shareholders at the EGM until the expiry of the term of office of the second session of the Board, which shall not exceed three years. Pursuant to the articles of association of the Company, Mr. Liu will be subject to re-election upon the expiry of his term of office.

The Board considered and approved the appointment of Mr. Liu as a member of the audit committee and the strategy development committee of the Board at the Board meeting held on the same date, subject to the approval of the appointment of Mr. Liu as a non-executive Director by the Shareholders at the EGM. The term of office shall commence from the date of approval of the election of Mr. Liu as a non-executive Director of the second session of the Board until the expiry of the term of the second session of the Board.

GENERAL

The Company will convene the EGM for the purposes of, among other things, seeking the Shareholders' approval for the appointment of Mr. Liu as a non-executive Director. The votes will be taken by poll at the EGM. A circular containing, among other things, details of the above proposed appointment, together with the notice of EGM, will be published on the websites of the Hong Kong Stock Exchange (http://www.hkexnews.hk) and the Company (https://www.biocytogen.com.cn).

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, January 27, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.